Cargando…
Antigen Loading (e.g., Glutamic Acid Decarboxylase 65) of Tolerogenic DCs (tolDCs) Reduces Their Capacity to Prevent Diabetes in the Non-Obese Diabetes (NOD)-Severe Combined Immunodeficiency Model of Adoptive Cotransfer of Diabetes As Well As in NOD Mice
Tolerogenic DCs (tolDCs) are being researched as a promising intervention strategy also in autoimmune diseases including type 1 diabetes (T1D). T1D is a T-cell-mediated, organ-specific disease with several well-defined and rather specific autoantigens, i.e., proinsulin, insulin, glutamic acid decarb...
Autores principales: | Funda, David P., Goliáš, Jaroslav, Hudcovic, Tomáš, Kozáková, Hana, Špíšek, Radek, Palová-Jelínková, Lenka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820308/ https://www.ncbi.nlm.nih.gov/pubmed/29503651 http://dx.doi.org/10.3389/fimmu.2018.00290 |
Ejemplares similares
-
Optimal Tolerogenic Dendritic Cells in Type 1 Diabetes (T1D) Therapy: What Can We Learn From Non-obese Diabetic (NOD) Mouse Models?
por: Funda, David P., et al.
Publicado: (2019) -
The Immunomodulatory Potential of tolDCs Loaded with Heat Shock Proteins
por: van Eden, Willem, et al.
Publicado: (2017) -
Histidine Decarboxylase Deficiency Prevents Autoimmune Diabetes in NOD Mice
por: Alkan, Manal, et al.
Publicado: (2015) -
Normal Incidence of Diabetes in NOD Mice Tolerant to Glutamic Acid Decarboxylase
por: Jaeckel, Elmar, et al.
Publicado: (2003) -
Immunotherapy with Tolerogenic Dendritic Cells Alone or in Combination with Rapamycin Does Not Reverse Diabetes in NOD Mice
por: Pujol-Autonell, Irma, et al.
Publicado: (2013)